Work

Combined ibrutinib and venetoclax for treatment of patients with ibrutinib‐resistant or double‐refractory chronic lymphocytic leukaemia

Year: 2022

Type: article

Study design: Observational Study

Source: British Journal of Haematology

DOI: 10.1111/bjh.18357

Authors: Paul J. Hampel, Kari G. Rabe, Timothy G. Call, Wei Ding, Jose F. Leis, Saad S. Kenderian, Eli Muchtar, Yucai Wang, Amber B. Koehler, Ricardo Parrondo, Susan M. Schwager, Min Shi, Esteban Braggio, Susan L. Slager, Neil E. Kay, Sameer A. Parikh

Institutions: Mayo Clinic, Mayo Clinic Hospital, Mayo Clinic Comprehensive Cancer Center (Arizona), Mayo Clinic in Florida, Mayo Clinic Comprehensive Cancer Center (Florida)

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4285586899

FWCI: 2.663

Cites: 15

Cited by: 24

Related to: 10